Skip to main content
. 2021 Dec 6;12:788558. doi: 10.3389/fphar.2021.788558

FIGURE 4.

FIGURE 4

UDCA ameliorates hepatic inflammation in NASH independent of steatosis. (A) Research scheme of UDCA in the treatment of HFHC-diet–induced NASH (n = 5 for each group). (B) UDCA treatment significantly lowered serum ALT and AST levels of NASH mice but not body weight and liver weight. (C) UDCA treatment ameliorated hepatic inflammation in NASH mice in a dose-dependent pattern but not steatosis. (D) Gross morphology, H&E, and Oil red O staining of hepatic tissue from mice in ND-control group, HFHC-control group, and different doses of UDCA treatment group. Values represent mean ± standard deviation with *p < 0.05, **p < 0.01, ****p < 0.000 and ns vs HFHC-control group. Abbreviation: UDCA, ursodeoxycholic acid; NASH, non-alcoholic steatohepatitis; HFHC, high-fat high-cholesterol; ALT, alanine transaminase; AST, aspartate transaminase; ND, normal diet; ns, not significantly.